OneHP Platform
OneHP by Aragen: One Platform. Ultra-High Containment.
From milligram discovery to multi-kilogram GMP supply — high-potent payloads, linker payloads and bioconjugation, without your molecule ever leaving the facility.
Every handoff costs months — and momentum
High-potency molecules are now mainstream science: nearly 65% of oncology candidates in development are highly potent, and the global HP molecule market continues to grow.
Yet most programs still move between three separate partners — discovery chemistry, process development and GMP supply — re-qualifying containment and re-validating methods at every transfer. Add ADC ambitions, and few sites even qualify at the containment thresholds these molecules demand.
One partner. One containment standard. One quality system.
OneHP unifies discovery, development, analytical and cGMP manufacturing on a single integrated platform — so your high-potency molecule advances without ever changing hands.
Platform at a Glance
| Stage | Scale | Explore (Links) |
|---|---|---|
| Discovery chemistry | Up to 10gm | OneHP Discovery → |
| Non-GMP process development & scale-up | Up to 500gm | OneHP Development & Manufacturing → |
| cGMP manufacturing | 500gm to 5kg per batch; ~500–600kg annual capacity | OneHP Development & Manufacturing → |
Facility & Containment
- ~15,000 sq ft, purpose-built OEB-6 facility in Hyderabad, India
- Ultra-high containment: potent-compound handling systems with five levels of cascading protection, supporting occupational exposure limits (OELs) up to 10 ng/m³
- SafeBridge-qualified systems and operating procedures
Built for What’s Next: ADCs and Bioconjugation
Antibody-drug conjugates (ADCs) are among the fastest-growing therapeutic modalities, driving demand for integrated high potent molecule discovery and development expertise across chemistry and biology.
OneHP platform can deliver the linker-payload synthesis chemistry and powers ADC and all other potent drug conjugate discovery and development programs and is further expanding to provide discovery scale ADC/PDC/DAC/AOC bioconjugation capabilities
OneHP platform together with inhouse antibody/protein production and bioconjugation servicesAragen enables seamless discovery and development of new generation targeted high potent drug (ADC/PDC/DAC/AOC) candidates. The OneHP platform can provide discovery services starting from high-potent linker-payload chemistry till bioconjugation journey, under one roof.
Outcomes That Matter to Your Program
Reduce Risk
One integrated partner from linker-payload design through conjugation and GMP supply — no vendor handoffs, no revalidation cycles, no re-onboarding of a new team at each stage.
Ensure Continuity
Experienced scientists guide payload selection, linker design and route strategy from day one — so scalability and containment are engineered in, not discovered late.
Accelerate Timelines
Knowledge follows your molecule. The same platform that synthesizes your first milligrams characterizes your conjugate and manufactures your kilograms.
